Javier Pinilla-Ibarz, MD
Enriched profileSenior Member, Moffitt Cancer Center · Moffitt Cancer Center
Javier Pinilla-Ibarz is Senior Member, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 483 publications with 13,371 citations (h-index 55).
Data verified 23 Oct 2026
Overview
Updated 27 Oct 2026
Javier Pinilla-Ibarz, MD, is Senior Member, Moffitt Cancer Center. The public record shows 483 publications with 13,371 citations (h-index 55), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents industry payments reported by 35 companies.
- Most recent indexed publication: 2026 · Case reports in pathology
- Top research focus: Chronic Lymphocytic Leukemia Research
- Open Payments reporting from 35 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 163.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Updated 26 Oct 2026
35 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Lilly USA, LLCProgram year202532 payments$60,972openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202525 payments$44,070openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202521 payments$25,213openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
92%Kinase inhibitor82.3%Calquence24%Imbruvica22%Brukinsa18%Imatinib Mesylate13%Bosulif8%Jaypirca8%Sprycel7%Part D<11 patientsBCL-2 Inhibitor9.6%Venclexta100%Part D<11 patientsDermatology
8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 26 Oct 2026
96 congress contributions (2008–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 26 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Successful Zanubrutinib Monotherapy in a Rare CNS Presentation of Relapsed CLL.
Case reports in hematology
Article2026 - Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Hematology (Amsterdam, Netherlands)
Article2025 - Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Blood cancer discovery
Article2024 - History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience.
Journal of cancer research and clinical oncology
Article2023
Most-cited works
by citation count (OpenAlex)- 01A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasArticle1,142 citations2013
- 02Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsArticle876 citations2019
- 03
- 04
- 05The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune toleranceArticle452 citations2008
Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 26 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/javier-pinilla-ibarz-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
moffitt.org/research-science/researchers/javier-pinilla
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Editorial & leadership roles
journal and society appointments- Head of Lymphoma Section
Department of Malignant Hematology, Moffitt Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Department of Oncologic Sciences, College of Medicine, University of South Florida
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vumedi.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- Patient Empowerment Network / Leukemia & Lymphoma Society webinar
"Fact or Fiction? CLL Treatment and Side Effects"
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗ - verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Nikhil Khushalani, MD
Moffitt Cancer Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center